Head-to-head evidence
Sacituzumab Govitecan vs Sacituzumab Tirumotecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT02574455 · Phase 3 · completed
Participants were randomized to sacituzumab govitecan or physician’s-choice chemotherapy, with 267 and 262 participants assigned respectively, but treatment was not blinded. The primary clinical endpoint was progression-free survival assessed by an independent review committee and was met: median progression-free survival was 5.6 versus 1.7 months, with p<0.0001; the open-label design supports a moderate rather than strong evidence grade.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Sacituzumab Tirumotecan
Developed by Merck & Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04152499 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sacituzumab Govitecan's landscape · Sacituzumab Tirumotecan's landscape